HepNet patient registry- secondary prevention of hepatic encephalopathy

• Conditions: Hepatic Encephalopathy; K72.9; Hepatic failure, unspecified

• Registration Number: DRKS00009691
• Lead Sponsor: Deutsche Leberstiftung

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2015-11-23
• Study Completion: 2017-03-31
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 115

Inclusion Criteria

Patients (> 18 years) with symptomatic hepatic encephalopathy, which required hospitalization in the last 3 months

Exclusion Criteria

hospitalization at baseline.
max. 50 patients will be enrolled with MELD> 20 (Should this have a strong negative impact on the recruitment, the number can be increased).

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Period until the re-hospitalization because of acute episodes of clinically manifest hepatic encephalopathy

Secondary Outcome Measures

Name	Time	Method
Frequencies of the decline of the baseline Westhaven criteria<br>2. Change in West Haven criteria with respect to baseline <br>3. Changes in PSE Syndrome Test compared to baseline<br>4. Changes of the flicker frequency compared to baseline<br>5. Detection of important influencing factors on disease progression (genetic analysis, Demographics)<br>6. Comparison of disease progression between the forms of therapy (administration vs. non-delivery of a drug)<br>7. Application of relevant concomitant medications, time of first dose, duration, dose